NEW YORK, June 29, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, presented new clinical research today at the American Diabetes Association (ADA) 81^st Scientific Sessions, the premier diabetes conference for cutting-edge research and advances in diabetes care.

Dario's latest research examines the impacts of the company's artificial intelligence (AI)-driven personalization engine on user engagement and clinical outcomes for close to 10,000 members. Dario users were given access to a new product experience designed to drive better health habits and behaviors. Dario's AI engine delivered highly personalized interventions to drive user engagement based on app activity and utilization data. The results suggest that personalized interventions help users better understand the relationship between their behaviors and their health indicators, driving sustainable engagement and better clinical outcomes. After the new digital experience was introduced, both engagement and clinical outcomes improved. The research yielded the following outcomes on 9,794 users given access to the new product experience:

• User engagement increased by 56% compared to the engagement baseline of all users before the new digital experience, results remained stable for at least six months. Average ratios of high-blood glucose readings (180-400 mg/dL) were reduced by 12% over six months.

"Consistent self-management of health conditions is one of the most crucial healthy behaviors we can help our members develop, and also one of the most difficult. Customizing the experience of health management with real-time data and feedback to offer tangible, actionable insights drives better engagement which leads to positive behavior change and improved clinical outcomes," said Yifat Hershcovitz, Scientific and Clinical Director of DarioHealth and lead author of the study.

"This study offers yet more data supporting our personalized approach as a means to drive sustainable behavior change for improved clinical outcomes," said Omar Manejwala, M.D., Chief Medical Officer of DarioHealth and co-author of the study.

Dario presented a second study at the ADA Scientific Sessions on the impact of Dario's hyper-personalization platform on diabetes self-management, evaluating clinical outcomes for 11,101 high-risk Type 2 diabetic members after 12 months of engagement. The results were:

• Average ratio of target in-range readings increased significantly from 28.4% to 54.8%.
• Average number of days between blood glucose readings (Recency) for Dario members was 3.3 days

For registration inquiries or to find out how to access final program presentations, visit the ADA Scientific Sessions event website at https://professional.diabetes.org/scientific-sessions.

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. DarioHealth offers one of the most comprehensive digital therapeutics solutions on the market - covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform.

Dario's next-generation, AI-powered, digital therapeutic platform supports more than just an individual's disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software, and coaching to help individuals improve health and sustain meaningful outcomes.

Dario's unique user-centric approach to product design and engagement creates an unparalleled experience that is highly rated by users and delivers sustainable results.

The company's cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and utilizes a performance-based approach to improve its users' health.

On the path to better health, Dario makes the right thing to do the easy thing to do. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the company is using forward-looking statements in this press release when it discusses the research results and that the results demonstrate that personalized interventions help users better understand the relationship between their behaviors and their health indicators, driving sustainable engagement and better clinical outcomes. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact
Suzanne Bedell
VP Marketing
suzanne@dariohealth.com
+1-347-767-4220

Media Contact:
Josephine Galatioto
Josephine.Galatioto@russopartnersllc.com
+1-212-845-4262

SOURCE DarioHealth Corp.